Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

• ClinicalTrials.gov Identifier: NCT05501548
• Recruitment Status: Not yet recruiting
• First Posted: August 15, 2022
• Last Update Posted: April 7, 2023
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborators: AstraZeneca; McGuff Pharmaceuticals, Inc.; The Marcus Foundation
• Information provided by (Responsible Party): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Description

Brief Summary:

This is a study to evaluate the safety and clinical activity of the combination of olaparib and high-dose IV ascorbate, as second or later line of therapy, in castration resistant prostate cancer patients with no known DNA repair gene mutations (DDRm). In brief, the primary endpoint is PSA50 response , defined by a 50% reduction in PSA from baseline . The secondary endpoints are assessing the PSA doubling time, radiographic and PSA PFS, safety and tolerability as defined by the incidence of grade 3 to 5 toxicities, and measuring overall survival.

Condition or disease	Intervention/treatment	Phase
Prostate Cancer; Castration-resistant Prostate Cancer	Drug: Olaparib; Dietary Supplement: Vitamin C	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 15 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
• Estimated Study Start Date: May 2023
• Estimated Primary Completion Date: March 2028
• Estimated Study Completion Date: March 2028

Arms and Interventions

Arm	Intervention/treatment
Experimental: Olaparib and Vitamin C; Olaparib will be administered at 300 mg by mouth, twice daily; ascorbate will be administered at 1 g/kg IV twice weekly at least 24 hours apart, until objective disease progression or unacceptable toxicities or patient withdrawal for other reasons.	Drug: Olaparib; Olaparib 300mg by mouth twice daily; Other Names: Lynparza; AZD2281; KU-0059436; Dietary Supplement: Vitamin C; Ascorbic acid 1g/kg administered intravenously twice weekly; Other Names: Ascorbic acid; L-ascorbic acid; Ascor; A11GA01

Outcome Measures

Primary Outcome Measures :

1. PSA50 response [ Time Frame: up to 5 years ]
   Number of participants with metastatic castration resistance prostate cancer (mCRPC) who experience a 50% reduction in prostate specific antigen (PSA50) from baseline. PSA50 response will be defined as a decrease in the PSA to 50% less than the baseline PSA upon enrollment in the trial. The decrease must be confirmed by a second measurement at least 4 weeks apart. PSA values will be measured monthly during the trial.

Secondary Outcome Measures :

1. Safety and tolerability of olaparib in combination with IV ascorbic acid in patients with mCRPC [ Time Frame: up to 5 years ]
   Number of participants experiencing treatment-related adverse events as defined by NCI CTCAE v5.0.
2. PSA doubling time in patients with mCRPC receiving olaparib in combination with IV ascorbic acid [ Time Frame: up to 5 years ]
   Median number of months to PSA doubling from the initiation of therapy until the PSA has increased to 200% of baseline value, and confirmed with another measurement at least 4 weeks later, or death. The date of PSA doubling will be the first value recorded (not the confirmatory value).
3. Radiographic progression free survival (rPFS) of patients with mCRPC receiving olaparib in combination with IV ascorbic acid [ Time Frame: up to 5 years ]
   Number of months from initiation of therapy to date of first radiographic progression, death from any cause, or last patient evaluation. Radiographic progression will be defined as soft tissue disease progression by modified RECIST criteria 1.1 (baseline LN size must be >1.0 cm to be considered target or evaluable lesion) or by development of two or more new bone lesions not consistent with tumor flair for prostate cancer working group 3.
4. PSA progression free survival (PSA PFS) of patients with mCRPC receiving olaparib in combination with IV ascorbic acid [ Time Frame: up to 5 years ]
   Number of months to first PSA failure (two consecutive increases in PSA of 50% and >=5ng/mL above nadir) or death
5. Overall survival of patients with mCRPC receiving olaparib in combination with IV ascorbic acid [ Time Frame: up to 5 years ]
   Number of months from initiation of therapy to death due to any cause

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Have metastatic castration-resistant prostate cancer (prostate cancer progressing by PSA (rise by 25% on prior therapy) or imaging despite castrate levels of testosterone [<50 ng/dL] using standard measures of progression defined by Prostate Cancer Working Group33)
• Have a minimum PSA of 1 ng/mL
• Have a pathological diagnosis of prostate carcinoma
• Patients should continue receiving continuous hormonal ablation with surgical or medical castration with baseline testosterone <50ng/dL
• Patients may be receiving bone-targeted agents
• May have received multiple lines of therapy including radium 223, sipuleucel T, and up to 2 lines of chemotherapy (One of 2 lines may be for hormone sensitive metastatic prostate cancer or both can be for castration resistant).
• Age >= 18
• Have ECOG performance status 0-1 (Appendix A)
• Be able to take oral medication and willing to consider a port for ease of administration of ascorbate
• Must have progressed on one systemic line of treatment (can include LHRH agonist/antagonist or orchiectomy and one additional line of therapy (abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, etc))

• Have normal organ and marrow function measured within 28 days prior to administration of study treatment as defined below:

  • Absolute neutrophil count >1.5 x 109/L
  • Platelets ≥ 100,000/mm³
  • Hemoglobin ≥ 9g/dL with no blood transfusion in the past 28 days
  • Total bilirubin ≤ 1.5 ULN
  • AST (SGOT)/ALT(SGPT) ≤ 2.5 x ULN (≤5x ULN if with known liver metastases provided bilirubin is normal
  • Creatinine ≤ 1.6 x ULN (for patients with ≥1.6 x ULN, calculated or measured creatinine clearance must be ≥ 60 mL/minute (Cockcroft-Gault)

• Men of reproductive potential and those who are surgically sterilized (i.e. post- vasectomy) must agree to practice effective barrier contraception that has an expected failure rate of <1% during and for 6 months after discontinuation of study treatment. Female partners should also use a highly effective form of contraception ([see Appendix C for acceptable methods]) if they are of childbearing potential.

  • If condoms are used as a barrier contraceptive, a spermicidal agent should be added to ensure that pregnancy does not occur
• Have the ability to understand, and have given written informed consent before performance of any study-related procedures not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

Exclusion Criteria:

• Have a known DNA repair mutation (minimum list of genes that must be mutation negative for inclusion: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD45L). In addition, patients who have not completed germline and somatic testing to rule out such a mutation are ineligible until they have completed testing. If tissue or liquid ctDNA sequencing was not previously done, testing using the Foundation One liquid biopsy test or an equivalent FDA-approved test is acceptable as standard of care.

  • DNA repair mutation variant of unknown significance (VUS) allowed
• Have had known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.
• No prior olaparib, rucaparib, or other PARP inhibitor
• Have had major surgery within 2 weeks of dosing of investigational agent
• Have had palliative radiation or another biological cancer therapy within 2 weeks prior to the first dose of study drug (2 week wash out required)
• Patients receiving any systemic chemotherapy or radiotherapy within 3 weeks prior to study treatment
• Have received other investigational drugs within 14 days prior to enrollment.
• Is expected to require chemotherapy or radiation for pain palliation in the next 12 weeks.
• Have used or plan concomitant use of the following medications in the past 6 months prior to enrollment: 5-alpha reductase inhibitors unless subject has been taking stable dose of medication for prior 6 months
• Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks. See the following link for a complete list of known CYP3A inhibitors: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
• Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents. See the following link for a complete list of known CYP3A inhibitors:https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers

• Have moderate or severe cardiovascular disease:

  • Has the presence of cardiac disease, including a myocardial infarction within six months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension.
  • Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTc prolongation >500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome.
• Have uncontrolled intercurrent illness, including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Other malignancy unless curatively treated with no evidence of disease for >5 years except adequately treated non-melanoma skin cancer
• Persistent toxicities (>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia
• Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML
• Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent
• Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
• Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).
• Patients with known active hepatitis (i.e. Hepatitis B or C)
• Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
• Patients with a known hypersensitivity to olaparib or any of the excipients of the product.

Contacts and Locations

Contacts

Contact: Kathy Schultz, RN; 410-614-9482; kschult3@jhmi.edu

Locations

United States, District of Columbia

Sibley Memorial Hospital

Washington, District of Columbia, United States, 20016

Contact: Jan Powers, MSN 202-660-6324 jpower22@jhmi.edu

Principal Investigator: Channing Paller, MD

United States, Maryland

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, United States, 21287

Contact: Kathy Schultz, RN 410-614-9482 kschult3@jhmi.edu

Principal Investigator: Channing Paller, MD

Sponsors and Collaborators

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

AstraZeneca

McGuff Pharmaceuticals, Inc.

The Marcus Foundation

Investigators

• Principal Investigator: Channing Paller, MD; Johns Hopkins University

More Information

• Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• ClinicalTrials.gov Identifier: NCT05501548
• Other Study ID Numbers: J21127; IRB00292465 ( Other Identifier: JHM IRB ); ESR 19-20448 ( Other Identifier: AstraZeneca )
• First Posted: August 15, 2022
• Last Update Posted: April 7, 2023
• Last Verified: April 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins:

olaparib; ascorbic acid; PARP; PARP-inhibitor

Additional relevant MeSH terms:

Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Ascorbic Acid; Olaparib; Vitamins; Micronutrients; Physiological Effects of Drugs; Antioxidants; Molecular Mechanisms of Pharmacological Action; Protective Agents; Poly(ADP-ribose) Polymerase Inhibitors; Enzyme Inhibitors; Antineoplastic Agents